APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025180 pages

Choose your research edition.

Industry ResearchRecombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein include Sunshine Guojian Pharmaceutical(Shanghai), Celgen Biopharma, Hisun Pharm, Pfizer, Amgen and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Segment by Company

Sunshine Guojian Pharmaceutical(Shanghai)

Celgen Biopharma

Hisun Pharm

Pfizer

Amgen

AbbVie

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Segment by Type

12.5mg per Vial

25mg per Vial

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Segment by Application

Retail Pharmacies

Hospital and Clinic

Specialist Medical Centre

Other

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Trends Table 2. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Drivers Table 3. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Opportunities and Challenges Table 4. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Restraints Table 5. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Manufacturers Table 9. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Manufacturers, Product Type & Application Table 13. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 12.5mg per Vial Table 17. Major Manufacturers of 25mg per Vial Table 18. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type (2021-2026) & (K Units) Table 20. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type (2027-2032) & (K Units) Table 21. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Type (2021-2026) Table 22. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Type (2027-2032) Table 23. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type (2021-2026) & (K Units) Table 25. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type (2027-2032) & (K Units) Table 26. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Type (2021-2026) Table 27. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Retail Pharmacies Table 29. Major Manufacturers of Hospital and Clinic Table 30. Major Manufacturers of Specialist Medical Centre Table 31. Major Manufacturers of Other Table 32. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application (2021-2026) & (K Units) Table 34. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application (2027-2032) & (K Units) Table 35. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Application (2021-2026) Table 36. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Application (2027-2032) Table 37. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application (2021-2026) & (K Units) Table 39. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application (2027-2032) & (K Units) Table 40. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Application (2021-2026) Table 41. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Application (2027-2032) Table 42. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Region (2021-2026) & (K Units) Table 44. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Region (2021-2026) Table 45. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2026) & (K Units) Table 49. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2027-2032) & (K Units) Table 50. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2026) & (K Units) Table 52. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2027-2032) & (K Units) Table 59. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Region (2021-2026) Table 63. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Region (2027-2032) Table 64. Sunshine Guojian Pharmaceutical(Shanghai) Company Information Table 65. Sunshine Guojian Pharmaceutical(Shanghai) Business Overview Table 66. Sunshine Guojian Pharmaceutical(Shanghai) Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sunshine Guojian Pharmaceutical(Shanghai) Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio Table 68. Sunshine Guojian Pharmaceutical(Shanghai) Recent Development Table 69. Celgen Biopharma Company Information Table 70. Celgen Biopharma Business Overview Table 71. Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio Table 73. Celgen Biopharma Recent Development Table 74. Hisun Pharm Company Information Table 75. Hisun Pharm Business Overview Table 76. Hisun Pharm Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Hisun Pharm Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio Table 78. Hisun Pharm Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio Table 83. Pfizer Recent Development Table 84. Amgen Company Information Table 85. Amgen Business Overview Table 86. Amgen Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Amgen Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio Table 88. Amgen Recent Development Table 89. AbbVie Company Information Table 90. AbbVie Business Overview Table 91. AbbVie Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. AbbVie Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio Table 93. AbbVie Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Distributors List Table 97. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Image Figure 2. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales (2021-2032) & (K Units) Figure 5. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 12.5mg per Vial Image Figure 9. 25mg per Vial Image Figure 10. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Type (2021-2032) Figure 13. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Type (2021-2032) Figure 16. Retail Pharmacies Image Figure 17. Hospital and Clinic Image Figure 18. Specialist Medical Centre Image Figure 19. Other Image Figure 20. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Application (2021-2032) Figure 23. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Application (2021-2032) Figure 26. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Country (2021-2032) Figure 28. U.S. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Country (2021-2032) Figure 33. Germany Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Country (2021-2032) Figure 40. China Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Country (2021-2032) Figure 48. Brazil Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032) & (US$ Million) Figure 59. North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032) & (US$ Million) Figure 61. Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 12.5mg per Vial
  • 25mg per Vial
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Specialist Medical Centre
  • Other
Companies covered
  • Sunshine Guojian Pharmaceutical(Shanghai)
  • Celgen Biopharma
  • Hisun Pharm
  • Pfizer
  • Amgen
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market Dynamics
  1. 2.1 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Trends
  2. 2.2 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Drivers
  3. 2.3 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Opportunities and Challenges
  4. 2.4 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Restraints
3 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market by Manufacturers
  1. 3.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Tier 1, Tier 2, and Tier 3
4 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market by Type
  1. 4.1 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Type Introduction
  2. 4.1.1 12.5mg per Vial
  3. 4.1.2 25mg per Vial
  4. 4.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type
  5. 4.2.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Type (2021-2032)
  7. 4.2.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Type (2021-2032)
  8. 4.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type
  9. 4.3.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Type (2021-2032)
  11. 4.3.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Type (2021-2032)
5 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Market by Application
  1. 5.1 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Specialist Medical Centre
  5. 5.1.4 Other
  6. 5.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application
  7. 5.2.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Application (2021-2032)
  9. 5.2.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Market Share by Application (2021-2032)
  10. 5.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application
  11. 5.3.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Application (2021-2032)
  13. 5.3.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Application (2021-2032)
6 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Region
  1. 6.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region
  1. 7.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region
  2. 7.1.1 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sunshine Guojian Pharmaceutical(Shanghai)
  2. 8.1.1 Sunshine Guojian Pharmaceutical(Shanghai) Company Information
  3. 8.1.2 Sunshine Guojian Pharmaceutical(Shanghai) Business Overview
  4. 8.1.3 Sunshine Guojian Pharmaceutical(Shanghai) Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sunshine Guojian Pharmaceutical(Shanghai) Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio
  6. 8.1.5 Sunshine Guojian Pharmaceutical(Shanghai) Recent Developments
  7. 8.2 Celgen Biopharma
  8. 8.2.1 Celgen Biopharma Company Information
  9. 8.2.2 Celgen Biopharma Business Overview
  10. 8.2.3 Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Celgen Biopharma Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio
  12. 8.2.5 Celgen Biopharma Recent Developments
  13. 8.3 Hisun Pharm
  14. 8.3.1 Hisun Pharm Company Information
  15. 8.3.2 Hisun Pharm Business Overview
  16. 8.3.3 Hisun Pharm Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hisun Pharm Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio
  18. 8.3.5 Hisun Pharm Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Value Chain Analysis
  2. 9.1.1 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Production Mode & Process
  6. 9.2 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Distributors
  9. 9.2.3 Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst